Prediction: The Trump Bull Market Will Soon End -- But These 2 Stocks Will Keep Winning Anyway

The article argues the Trump-led bull market may be nearing an end as the S&P 500 trades near record valuation levels and inflation pressures remain elevated. It highlights Eli Lilly and Johnson & Johnson as defensive winners, citing Lilly’s obesity-drug growth, new oral weight-loss drug Foundayo, and positive phase 3 retatrutide data, while J&J posted nearly 10% total sales growth to more than $24 billion with 11% innovative-medicine growth. The piece is largely an investor commentary on positioning rather than new market-moving facts.

Analysis

The real market implication is not simply “defensive healthcare wins,” but that the current tape is starting to reward companies with visible pricing power, mix shift, and cash-flow durability while punishing anything dependent on multiple expansion. That favors large-cap healthcare over long-duration growth, especially if inflation stays sticky and rates stop falling. In that regime, LLY and JNJ are less about pure upside optionality and more about relative safety with continued earnings revisions, which can attract incremental ownership from crowded AI/megacap flows once volatility rises.

LLY remains the cleaner momentum expression, but the second-order trade is broader than the stock itself: every additional month of GLP-1 demand outstripping supply supports an ecosystem of contract manufacturers, specialty pharmacies, and oral-drug enabling technologies, while pressuring legacy diabetes, bariatric surgery, and some food/consumer wellness categories. The key risk is not demand—it is execution and normalization. If supply catches up faster than expected or insurers intensify utilization management, the market may compress forward multiples even while fundamentals stay strong.

JNJ is the more interesting contrarian because it is not priced as a growth story, yet it has enough scale in innovation and medtech to compound through a slowdown. The market may be underestimating how a diversified healthcare bellwether becomes a natural parking place when investors rotate out of expensive growth and into earnings resilience. That said, the catalyst window is months, not days: this is a relative-performance trade that needs macro stress or a growth drawdown to fully work.

The biggest missed point is that a late-cycle equity market can still grind higher in select pockets even as breadth deteriorates. In that scenario, the winners are the names with quasi-consumable demand and self-funding R&D, not the ones relying on a benign discount-rate backdrop. If the inflation narrative re-accelerates, these names should outperform first; if macro remains risk-on, they can still lag the highest-beta AI complex, so the trade should be framed as a barbell hedge rather than an outright market call.

Key Decisions for Investors

• Add LLY on any 3-5% pullback over the next 2-4 weeks; target a 6-9 month hold for earnings-revision upside. Risk/reward remains favorable so long as the market continues to pay up for secular growth with durable demand.
• Initiate a relative-value long LLY / short XLV basket of lower-growth pharma and managed care names for 3-6 months. The thesis is that GLP-1 leadership and pipeline optionality should keep LLY outperforming even if healthcare as a sector merely tracks the market.
• Use JNJ as a defensive rotation long against a short in high-multiple software or unprofitable AI names over 1-3 months. If rates stay elevated or growth breadth deteriorates, JNJ’s earnings durability should outperform on a drawdown basis.
• Buy JNJ Jan-2027 call spreads instead of stock for a lower-carry way to express a slow-burn defensive rerating. This fits a scenario where multiple expansion comes from a market rotation rather than company-specific upside alone.
• Avoid KVUE as a direct expression of this view; it lacks the operating leverage and innovation mix to benefit from the same regime. If you want consumer defensiveness, the cleaner trade is healthcare quality, not stable but low-growth branded consumer exposure.